ClinicalTrials.gg
CompletedNCT00712933Updated Dec 5, 2019Results posted

A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057

A Phase 3 interventional study of belimumab in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 110 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-05.

Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
738
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
5th of 36
738 · median 81
Started
2008
with 2 others
Phase 3
11 of 36
none open now
Registered
6th of 36
by date
Lead sponsor
7 of 36
Human Genome Sciences Inc., a GSK Company

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 5th largest by enrollment, is one of 3 that started in 2008, is one of 11 in phase 3, and was the 6th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This is a long-term continuation study to provide continuing treatment to subjects with SLE.

Read the detailed description

This trial is a long-term continuation study to provide continuing treatment to subjects with System Lupus Erythematosus (SLE).

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • SLE
  • Belimumab
  • Antibodies
  • Systemic Lupus Erythematosus
  • Lupus
  • Autoimmune Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed the HGS 1006-C1056 or HGS 1006-C1057 protocol through the Week 72 or Week 48 visits, respectively.

Exclusion criteria

Exclusion Criteria:

  • Have developed any other medical disease or condition that has made the patient unsuitable for this study in the opinion of their physician.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
738 participants (actual)

Study arms

  • Experimental
    1

    1 mg/kg dose of belimumab given IV every 28 days.

    Drug: belimumab

  • Experimental
    2.

    10 mg/kg dose of belimumab given IV every 28 days.

    Drug: belimumab

Interventions

  • Recombinant, fully human, monoclonal antibody Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days.

    Also known as: LymphoStat-B™, HGS1006

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AE)

    An adverse event is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example: increase in frequency or severity) of preexisting conditions. Participants with incidences of any event at any time post-baseline are presented by yearly interval. Only treatment-emergent AEs are summarized.

    Time frame: Up to 9 years

  2. AE Rates by System Organ Class (SOC) During the Study

    AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent AEs are summarized. The event rate of an AE was calculated as the number of events per 100 participant years. Participant years were calculated as sum across all participants (\[last visit of interval day - first visit of interval day + 1\] divided by365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.

    Time frame: Up to 9 years

  3. Number of Participants With Serious Adverse Events (SAE)

    An adverse event resulting in death, is life threatening (ie, an immediate threat to life), inpatient hospitalization, prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or any other situation which is medically important is categorized as SAE. Only treatment-emergent AEs are summarized.

    Time frame: Up to 9 years

  4. SAE Rates by SOC During the Study

    SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The event rate of an SAE was calculated as the number of events per 100 participant years. Participants years were calculated as = sum across all participants (\[last visit of interval day - first visit of interval day + 1\] divided by 365). Participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.

    Time frame: Up to 9 years

  5. Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point

    Time frame: Baseline and up to 9 years

  6. Change From Baseline in Platelets (Plt), Lymphocytes (Lymp), Leukocytes (Leu), Eosinophils (Eos), Basophils (Baso), Monocytes (Mono), Neutrophils (Neu), Neutrophils Band Form (NeuBF), Neutrophils Segmented (NeuS) at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Plt, Lymp, Leu, Eos, Baso, Mono, Neu, NeuBF, and NueS are summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  7. Change From Baseline in Hemoglobin (Hg) at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Hg is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  8. Change From Baseline in Hematocrit at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks). Change from Baseline in Hematocrit is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  9. Change From Baseline in Erythrocytes (Eryth) at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Erythrocytes is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  10. Change From Baseline in Calcium (Ca), Carbon Dioxide (CO2), Chloride, Magnesium (Mg), Phosphate (Phos), Potassium (K), Sodium (Na) at the Indicated Time Points

    Electrolytes parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 electrolytes parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Ca,CO2, Chloride, Mg, Phos, K and Na were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  11. Change From Baseline in Blood Urea Nitrogen/Creatinine (BUN/Cr) at the Indicated Time Points

    Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in BUN/Cr is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Baseline and up to 9 years

  12. Change From Baseline in Albumin (Alb) and Protein (Pro) at the Indicated Time Points

    Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Alb and Protein were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  13. Change From Baseline in BUN and Glucose at the Indicated Time Points

    Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in BUN and Glucose were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  14. Change From Baseline in Creatinine (Cr) and Urate at the Indicated Time Points

    Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Cr and Urate were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  15. Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels

    Liver function parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 liver function parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in ALT, ALP, AST, GGT and LDH were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  16. Change From Baseline in Bilirubin (Bili) Levels

    Liver function parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 liver function parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Bili were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  17. Change From Baseline in Immunoglobulin G (IgG) Levels

    Immunoglobulin (Ig) parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 Ig parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Ig G were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

    Time frame: Baseline and up to 9 years

  18. Number of Participants With Immunogenic Response by Year

    Immunogenic response was analyzed using serum samples for anti-belimumab antibody measurements in MITT population. Categories of response are Negative, Transient Positive (+) means single + response that does not occur at the final assessment, and Persistent + means + response that occurs at least 2 consecutive assessments or a single result at the final assessment. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to 9 years

  19. Number of Participants With IgG Values Below the Lower Limit of Normal by Year

    Blood samples were collected to evaluate IgG levels at Baseline and at Weeks 12, 24 and 48 during Year 1. From Year 2-9, IgG was evaluated at Week 24 and 48 ; Exit visit and at follow-up visit (up to 8 weeks post last infusion). Number of participants with IgG immunoglobulin values below the LLN at each one year interval are presented. Baseline includes Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. If a participant had more than one response within a year, then the last response within the year interval (usually the Week 48 assessment) was summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to 9 years

  20. Number of Participants With Shifts From Baseline in Prednisone and Other Steroids Dose by Visit

    Participants who had improving SLE disease activity for at least 8 weeks, at the investigator's discretion, the steroid dose was reduced by reduction to 7.5 mg/day. If the participant continued to have stable or improving disease activity after 4 weeks on a reduced dose, then the investigator considered reducing the dose again. Baseline includes extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. Number of participants with shifts from Baseline total daily dose category by visit is summarized.

    Time frame: Up to 9 years

  21. Number of Participants With Any SLICC/ ACR Damage Index Worsening (Change > 0) From Baseline by Visit

    The SLICC/ACR Damage Index was assessed every 48 weeks and at the exit visit as a measure of disease activity. It was developed to assess the accumulated damage since the onset of the disease. The number of participants with worsening in their SLICC/ACR Damage Index score compared with Baseline have been presented. Worsening was defined as a change in score (post-Baseline visit score - Baseline score) \> 0. Baseline includes extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. For years in which a participant was withdrawn from the study, the exit visit assessment was used in place of the Week 48 assessment for the year. This value was not carried forward through later years. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

    Time frame: Up to 9 years

07

Results

Posted Jan 16, 2018

Participant flow

This was a multi-center, continuation trial of belimumab and was conducted at 115 centers in 28 countries. Participants with Systemic Lupus Erythematosus (SLE), who had completed the Phase 3 HGS1006-C1056 or HGS1006-C1057 trial or participants who had previously received subcutaneous belimumab in Protocol HGS1006-C1070 were included in this trial.

Participant flow — Overall Study
MilestoneBelimumab 10mg/kg IV
Started735
Completed368
Not completed367
Withdrew: Adverse event69
Withdrew: Lack of efficacy6
Withdrew: Lost to follow-up22
Withdrew: Non-compliance with study drug13
Withdrew: Other pregnancy37
Withdrew: Sponsor decision14
Withdrew: Withdrew consent4
Withdrew: Hip replacement surgery1
Withdrew: Involved in clinical research3
Withdrew: Participant hospitalized1
Withdrew: Participant travelled overseas2
Withdrew: Death of patient1
Withdrew: Other physician decision1
Withdrew: Not committed to contraception1
Withdrew: Participant received medication1
Withdrew: Physician decision36
Withdrew: Protocol violation4
Withdrew: Withdrawal by subject151

Outcome measures

PrimaryNumber of Participants With Adverse Events (AE)

An adverse event is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example: increase in frequency or severity) of preexisting conditions. Participants with incidences of any event at any time post-baseline are presented by yearly interval. Only treatment-emergent AEs are summarized.

Time frame:
Up to 9 years
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE)
ParticipantsBelimumab 10mg/kg IV
Any-time post Baseline,n=735706
Year 0-1,n=735617
Year 1-2 ,n =701502
Year 2-3, n= 620441
Year 3-4,n= 514344
Year 4-5,n= 442261
Year 5-6, n =345181
Year 6-7, n= 21992
Year 7-8, n = 6526
Year 8 plus,n = 63
PrimaryAE Rates by System Organ Class (SOC) During the Study

AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent AEs are summarized. The event rate of an AE was calculated as the number of events per 100 participant years. Participant years were calculated as sum across all participants (\[last visit of interval day - first visit of interval day + 1\] divided by365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.

Time frame:
Up to 9 years
Reported as:
Number · Adverse events per 100 participant years
AE Rates by System Organ Class (SOC) During the Study
Adverse events per 100 participant yearsBelimumab 10mg/kg IV
Infections and infestations101.8
Gastrointestinal disorders32.8
Musculoskeletal and connective tissuedisorder32.8
Nervous system disorders22.6
Skin and subcutaneous and tissue disorders22.5
Respiratory,thoracic and mediastinal disorder14.9
Vascular disorders13.3
General disorders and administration sitecondition11.8
Injury, poisoning andprocedural complications11.5
Blood and lymphatic system disorders7.5
Eye disorders6.6
Reproductive system and breast disorders6.4
Investigations5.8
Psychiatric disorders5.6
Renal and urinary and disorder5.3
Metabolism and nutrition disorder3.6
Cardiac disorders3.0
Ear and labyrinth disorder2.4
Neoplasms benign,malignant andunspecified2.2
Hepatobiliary disorders1.8
Immune system disorder1.2
Endocrine disorders1.0
Social circumstances0.7
Congenital, familial and genetic disorders0.1
Pregnancy, puerperium and perinatal conditions0.1
Product Issues0.1
PrimaryNumber of Participants With Serious Adverse Events (SAE)

An adverse event resulting in death, is life threatening (ie, an immediate threat to life), inpatient hospitalization, prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or any other situation which is medically important is categorized as SAE. Only treatment-emergent AEs are summarized.

Time frame:
Up to 9 years
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAE)
ParticipantsBelimumab 10mg/kg IV
Any post-Baseline,n=735231
Year 0-1,n=73578
Year 1-2,n = 70158
Year 2-3,n = 62066
Year 3-4,n= 51444
Year 4-5 ,n= 44227
Year 5-6,n=34516
Year 6-7,n= 21911
Year 7-8,n= 651
Year 8 plus,n= 60
PrimarySAE Rates by SOC During the Study

SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The event rate of an SAE was calculated as the number of events per 100 participant years. Participants years were calculated as = sum across all participants (\[last visit of interval day - first visit of interval day + 1\] divided by 365). Participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.

Time frame:
Up to 9 years
Reported as:
Number · Adverse events per 100 participant years
SAE Rates by SOC During the Study
Adverse events per 100 participant yearsBelimumab 10mg/kg IV
Infections and infestations5.1
Blood and lymphatic system disorders1.0
Musculoskeletal and connective tissue disorder1.0
Gastrointestinal disorders1.0
Renal and urinary disorders0.8
Vascular disorders0.8
Injury, poisoning andprocedural complications0.8
General disorders and administration sitecondition0.6
Nervous system disorders0.6
Respiratory, thoracic and mediastinal disorder0.5
Cardiac disorders0.5
Skin and subcutaneous tissue disorders0.5
Neoplasms benign, malignant and unspecified0.4
Reproductive system and breast disorder0.4
Psychiatric disorders0.4
Hepatobiliary disorders0.3
Metabolism and nutrition disorders0.1
Pregnancy, puerperium and perinatal condition0.1
Endocrine disorders0.1
Immune system disorders0.1
Ear and labyrinth disorders0.1
Eye disorders0.1
PrimaryChange From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point

Time frame:
Baseline and up to 9 years
Reported as:
Mean · Seconds
Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points
SecondsBelimumab 10mg/kg IV
Year1,Week4,APTT,n=2080.7 ± 5.27
Year1,Week12,APTT,n=2082.1 ± 12.31
Year1,Week24,APTT,n=6860.1 ± 9.10
Year1,Week36,APTT,n=1932.5 ± 5.75
Year1,Week48,APTT,n=6660.8 ± 9.48
Year2,Week24,APTT,n=6252.7 ± 9.74
Year2,Week48,APTT,n=5722.7 ± 9.66
Year3,Week24,APTT,n=5213.4 ± 10.01
Year3,Week48,APTT,n=4703.9 ± 11.41
Year4,Week24,APTT,n=4223.5 ± 10.70
Year4,Week48,APTT,n=4124.2 ± 6.63
Year5,Week24,APTT,n=3834.1 ± 10.71
Year5,Week48,APTT,n=3493.5 ± 6.35
Year6,Week24,APTT,n=2923.8 ± 6.58
Year6,Week48,APTT,n=2774.3 ± 7.91
Year7,Week24,APTT,n=1776.4 ± 14.52
Year7,Week48,APTT,n=1314.1 ± 6.23
Year8,Week24,APTT,n=525.6 ± 7.54
Year8,Week48,APTT,n=134.2 ± 3.98
Year9,Week24,APTT,n=65.0 ± 6.39
Year9,Week48,APTT,n=19.0 ± NA
Exit, APTT,n=5863.2 ± 10.71
8 Week,Follow up,n=5243.4 ± 8.14
Year1,Week4,PT,n=205-0.22 ± 5.139
Year1,Week12,PT,n=2061.71 ± 19.533
Year1,Week24,PT,n=686-0.43 ± 8.267
Year1,Week36,PT,n=1930.13 ± 3.357
Year1,Week48,PT,n=666-0.45 ± 8.174
Year2,Week24,PT,n=6260.15 ± 11.528
Year2,Week48,PT,n=572-0.26 ± 8.925
Year3,Week24,PT,n=5210.12 ± 9.609
Year3,Week48,PT,n=4690.63 ± 14.334
Year4,Week24,PT,n=4220.06 ± 10.458
Year4,Week48,PT,n=4120.40 ± 4.228
Year5,Week24,PT,n=384-0.14 ± 10.810
Year5,Week48,PT,n=3490.61 ± 11.276
Year6,Week24,PT,n=2920.64 ± 8.023
Year6,Week48,PT,n=2780.85 ± 12.414
Year7,Week24,PT,n=1771.76 ± 14.272
Year7,Week48,PT,n=1310.36 ± 2.290
Year8,Week24,PT,n=521.21 ± 6.716
Year8,Week48,PT,n=130.52 ± 0.600
Year9,Week24,PT,n=60.50 ± 0.657
Year9,Week48,PT,n=11.00 ± NA
Exit,PT, n=5870.25 ± 9.973
8 Week, Follow up,n=5240.50 ± 4.965
PrimaryChange From Baseline in Platelets (Plt), Lymphocytes (Lymp), Leukocytes (Leu), Eosinophils (Eos), Basophils (Baso), Monocytes (Mono), Neutrophils (Neu), Neutrophils Band Form (NeuBF), Neutrophils Segmented (NeuS) at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Plt, Lymp, Leu, Eos, Baso, Mono, Neu, NeuBF, and NueS are summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · Billion cells per liter
Change From Baseline in Platelets (Plt), Lymphocytes (Lymp), Leukocytes (Leu), Eosinophils (Eos), Basophils (Baso), Monocytes (Mono), Neutrophils (Neu), Neutrophils Band Form (NeuBF), Neutrophils Segmented (NeuS) at the Indicated Time Points
Billion cells per literBelimumab 10mg/kg IV
Baso,Year1,Week4,n=6930.002 ± 0.0172
Baso,Year1,Week12,n=6940.002 ± 0.0187
Baso,Year1,Week24,n=6960.002 ± 0.0176
Baso,Year1,Week36,n=6820.002 ± 0.0179
Baso,Year1,Week48,n=6840.003 ± 0.0183
Baso,Year2,Week24,n=6290.004 ± 0.0190
Baso,Year2,Week48,n=5890.004 ± 0.0200
Baso,Year3,Week24,n=5330.005 ± 0.0165
Baso,Year3,Week48,n=4760.008 ± 0.0194
Baso,Year4,Week24,n=4460.007 ± 0.0192
Baso,Year4,Week48,n=4230.008 ± 0.0202
Baso,Year5,Week24,n=3890.007 ± 0.0191
Baso,Year5,Week48,n=3600.005 ± 0.0191
Baso,Year6,Week24,n=3060.006 ± 0.0184
Baso,Year6,Week48,n=2820.007 ± 0.0198
Baso,Year7,Week24,n=1810.007 ± 0.0211
Baso,Year7,Week48,n=1300.012 ± 0.0259
Baso,Year8,Week24,n=520.014 ± 0.0187
Baso,Year8,Week48,n=130.001 ± 0.0166
Baso,Year9,Week24,n=60.003 ± 0.0082
Baso,Year9,Week48,n=10.010 ± NA
Baso,Exit,n=6140.005 ± 0.0204
Baso,8 Week,Follow up,n=5320.009 ± 0.0253
Eos,Year1,Week4,n=6930.007 ± 0.1597
Eos,Year1,Week12,n=6940.003 ± 0.1595
Eos,Year1,Week24,n=6960.000 ± 0.1614
Eos,Year1,Week36,n=6820.020 ± 0.1866
Eos,Year1,Week48,n=6840.001 ± 0.1763
Eos,Year2,Week24,n=6290.004 ± 0.1605
Eos,Year2,Week48,n=589-0.004 ± 0.1858
Eos,Year3,Week24,n=533-0.011 ± 0.2074
Eos,Year3,Week48,n=476-0.026 ± 0.2053
Eos,Year4,Week24,n=446-0.041 ± 0.1792
Eos,Year4,Week48,n=423-0.047 ± 0.1676
Eos,Year5,Week24,n=389-0.035 ± 0.1949
Eos,Year5,Week48,n=360-0.045 ± 0.1807
Eos,Year6,Week24,n=306-0.046 ± 0.1801
Eos,Year6,Week48,n=282-0.037 ± 0.1976
Eos,Year7,Week24,n=181-0.046 ± 0.1710
Eos,Year7,Week48,n=130-0.020 ± 0.2276
Eos,Year8,Week24,n=52-0.017 ± 0.1753
Eos,Year8,Week48,n=13-0.041 ± 0.1130
Eos,Year9,Week24,n=6-0.088 ± 0.1078
Eos,Year9,Week48,n=1-0.040 ± NA
Eos, Exit, n=614-0.026 ± 0.1754
Eso, 8 Week Follow up, n=532-0.030 ± 0.1920
Leu,Year1,Week4,n=6960.16 ± 1.928
Leu,Year1,Week12,n=6970.19 ± 2.106
Leu,Year1,Week24,n=6970.04 ± 2.142
Leu,Year1,Week36,n=6820.05 ± 2.190
Leu,Year1,Week48,n=6840.02 ± 2.274
Leu,Year2,Week24,n=630-0.19 ± 2.287
Leu,Year2,Week48,n=589-0.11 ± 2.449
Leu,Year3,Week24,n=533-0.03 ± 2.544
Leu,Year3,Week24,n=4760.06 ± 2.393
Leu,Year4,Week24,n=446-0.01 ± 2.520
Leu,Year4,Week48,n=423-0.06 ± 2.661
Leu,Year5,Week24,n=3890.05 ± 2.430
Leu,Year5,Week48,n=360-0.06 ± 2.463
Leu,Year6,Week24,n=3060.04 ± 2.449
Leu,Year6,Week48,n=2820.17 ± 2.579
Leu,Year7,Week24,n=1810.12 ± 2.395
Leu,Year7,Week48,n=1300.48 ± 2.354
Leu,Year8,Week24,n=520.38 ± 2.761
Leu,Year8,Week48,n=13-0.65 ± 3.136
Leu,Year9,Week24,n=6-0.35 ± 3.422
Leu,Year9,Week48,n=1-3.90 ± NA
Leu, Exit, n=6140.18 ± 2.650
Leu, 8 Week Follow up,n=5320.21 ± 2.496
Lymp,Year1,Week4,n=6930.093 ± 0.5986
Lymp,Year1,Week12,n=6940.107 ± 0.6607
Lymp,Year1,Week24,n=6960.066 ± 0.6544
Lymp,Year1,Week36,n=6820.119 ± 0.6583
Lymp,Year1,Week48,n=6840.048 ± 0.6361
Lymp,Year2,Week24,n=6290.051 ± 0.6898
Lymp,Year2,Week48,n=5890.067 ± 0.6971
Lymp,Year3,Week24,n=5330.057 ± 0.6717
Lymp,Year3,Week48,n=4760.038 ± 0.6676
Lymp,Year4,Week24,n=4460.054 ± 0.6858
Lymp,Year4,Week48,n=4230.067 ± 0.7186
Lymp,Year5,Week24,n=3890.023 ± 0.6810
Lymp,Year5,Week48,n=3600.078 ± 0.7485
Lymp,Year6,Week24,n=3060.147 ± 0.7251
Lymp,Year6,Week48,n=2820.168 ± 0.7523
Lymp,Year7,Week24,n=1810.175 ± 0.7670
Lymp,Year7,Week48,n=1300.169 ± 0.6639
Lymp,Year8,Week24,n=520.300 ± 0.7553
Lymp,Year8,Week48,n=130.052 ± 0.5252
Lymp,Year9,Week24,n=6-0.032 ± 0.6156
Lymp,Year9,Week48,n=1-0.460 ± NA
Lymp,Exit,n=6140.128 ± 0.7808
Lymp,8 Week Follow up,n=5320.140 ± 0.7453
Mono,Year1,Week4,n=6930.025 ± 0.2108
Mono,Year1,Week12,n=6940.036 ± 0.2043
Mono,Year1,Week24,n=6960.028 ± 0.2127
Mono,Year1,Week36,n=6820.053 ± 0.2053
Mono,Year1,Week48,n=6840.050 ± 0.2069
Mono,Year2,Week24,n=6290.034 ± 0.1992
Mono,Year2,Week48,n=5890.050 ± 0.2172
Mono,Year3,Week24,n=5330.053 ± 0.2314
Mono,Year3,Week48,n=4760.084 ± 0.1994
Mono,Year4,Week24,n=4460.071 ± 0.2085
Mono,Year4,Week48,n=4230.076 ± 0.2040
Mono,Year5,Week24,n=3890.089 ± 0.2015
Mono,Year5,Week48,n=3600.088 ± 0.2044
Mono,Year6,Week24,n=3060.087 ± 0.2043
Mono,Year6,Week48,n=2820.086 ± 0.2063
Mono,Year7,Week24,n=1810.113 ± 0.2155
Mono,Year7,Week48,n=1300.134 ± 0.2090
Mono,Year8,Week24,n=520.173 ± 0.2014
Mono,Year8,Week48,n=130.021 ± 0.1503
Mono,Year9,Week24,n=60.022 ± 0.1931
Mono,Year9,Week48,n=1-0.120 ± NA
Mono, Exit,n=6140.083 ± 0.2157
Mono, 8 Week Follow up, n=5320.084 ± 0.2189
Neu,Yaer1,Week4,n=6880.024 ± 2.0482
Neru,Year1,Week12,n=6900.047 ± 2.1575
Neu,Year1,Week24,n=691-0.059 ± 2.1845
Neu,Year1,Week36,n=677-0.141 ± 2.1907
Neu,Year1,Week48,n=679-0.078 ± 2.3164
Neu,Year2,Week24,n=624-0.286 ± 2.2746
Neu,Year2,Week48,n=584-0.230 ± 2.3963
Neu,Year3,Week24,n=528-0.135 ± 2.4914
Neu,Year3,Week48,n=471-0.049 ± 2.3683
Neu,Year4,Week24,n=446-0.104 ± 2.3846
Neu,Year4,Week48,n=423-0.160 ± 2.5563
Neu,Year5,Week24,n=384-0.031 ± 2.3060
Neu,Year5,Week48,n=356-0.198 ± 2.3952
Neu,Year6,Week24,n=306-0.151 ± 2.3083
Neu,Year6,Week48,n=282-0.060 ± 2.4314
Neu,Year7,Week24,n=181-0.129 ± 2.3908
Neu,Year7,Week48,n=130-0.687 ± 3.0412
Neu,Year8,Week24,n=52-0.092 ± 2.3908
Neu,Year8,Week48,n=13-0.687 ± 3.0412
Neu,Year9,Week24,n=6-0.257 ± 2.9192
Neu,Year9,Week48,n=1-3.300 ± NA
Neu, Exit, n=609-0.006 ± 2.5612
Neu,8 Week Follow up,n=5280.001 ± 2.3935
NeuBF,Year1,Week4,n=40.013 ± 0.1473
NeuBF,Year1,Week12,n=40.073 ± 0.1106
NeuBF,Year1,Week24,n=5-0.000 ± 0.2699
NeuBF,Year1,Week36,n=40.045 ± 0.0465
NeuBF,Year1,Week48,n=20.105 ± 0.1909
NeuBF,Year2,Week24,n=10.120 ± NA
NeuBF,Year3,Week24,n=10.070 ± NA
NeuBF,Exit,n=20.465 ± 0.6435
NeuS,Year1,Week4,n=6930.021 ± 2.0450
NeuS,Year1,Week12,n=6940.051 ± 2.1519
NeuS,Year1,Week24,n=696-0.055 ± 2.1757
NeuS,Year1,Week36,n=682-0.139 ± 2.1819
NeuS,Year1,Week48,n=684-0.079 ± 2.3128
NeuS,Year2,Week24,n=629-0.289 ± 2.2609
NeuS,Year2,Week48,n=589-0.226 ± 2.3846
NeuS,Year3,Week24,n=533-0.130 ± 2.4736
NeuS,Year3,Week48,n=476-0.041 ± 2.3547
NeuS,Year4,Week24,n=446-0.097 ± 2.3804
NeuS,Year4,Week48,n=423-0.158 ± 2.5542
NeuS,Year5,Week24,n=389-0.024 ± 2.2893
NeuS,Year5,Week48,n=360-0.184 ± 2.3831
NeuS,Year6,Week24,n=306-0.147 ± 2.3029
NeuS,Year6,Week48,n=282-0.058 ± 2.4310
NeuS,Year7,Week24,n=181-0.151 ± 2.2248
NeuS,Year7,Week48,n=1300.191 ± 2.2514
NeuS,Year8,Week24,n=52-0.092 ± 2.3908
NeuS,Year8,Week48,n=13-0.687 ± 3.0412
NeuS,Year9,Week24,n=6-0.257 ± 2.9192
NeuS,Year9,Week48,n=1-3.300 ± NA
NeuS,Exit,n=614-0.008 ± 2.5501
NeuS,8 Week Followup,n=5320.007 ± 2.3824
Plt,Year1,Week4,n=6838.1 ± 38.82
Plt,Year1,Week12,n=6904.6 ± 43.63
Plt,Year1,Week24,n=687-0.5 ± 47.73
Plt,Year1,Week36,n=680-2.9 ± 50.25
Plt,Year1,Week48,n=677-9.3 ± 50.81
Plt,Year2,Week24,n=631-15.4 ± 53.80
Plt,Year2,Week48,n=583-20.3 ± 56.39
Plt,Year3,Week24,n=526-19.9 ± 57.88
Plt,Year3,Week48,n=476-13.4 ± 65.16
Plt,Year4,Week24,n=441-14.0 ± 59.05
Plt,Year4,Week48,n=420-18.2 ± 63.80
Plt,Year5,Week24,n=388-19.3 ± 61.49
Plt,Year5,Week48,n=360-17.9 ± 63.36
Plt,Year6,Week24,n=305-13.3 ± 61.54
Plt,Year6,Week48,n=282-13.4 ± 60.89
Plt,Year7,Week24,n=181-15.3 ± 63.95
Plt,Year7,Week48,n=130-16.3 ± 70.75
Plt,Year8,Week24,n=52-2.3 ± 80.69
Plt,Year8,Week48,n=13-29.9 ± 88.66
Plt,Year9,Week24,n=6-5.0 ± 82.67
Plt,Year9,Week48,n=157.0 ± NA
Plt,Exit,n=613-11.0 ± 64.36
Plt,8Week Followup,n=530-11.2 ± 60.57
PrimaryChange From Baseline in Hemoglobin (Hg) at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Hg is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · Gram per liter (g/L)
Change From Baseline in Hemoglobin (Hg) at the Indicated Time Points
Gram per liter (g/L)Belimumab 10mg/kg IV
Hg,Year1, Week 4,n=697-0.3 ± 7.05
Hg,Year1,Week12,n=6980.1 ± 8.75
Hg,Year1,Week24,n=6990.1 ± 9.48
Hg,Year1,Week36,n=6880.3 ± 9.90
Hg,Year1,Week48,n=6861.0 ± 11.03
Hg,Year2,Week24,n=6351.0 ± 11.31
Hg,Year2,Week48,n=5911.3 ± 12.12
Hg,Year3,Week24,n=5342.2 ± 12.79
Hg,Year3,Week48,n=4782.9 ± 12.67
Hg,Year4,Week24,n=4462.6 ± 12.93
Hg,Year,Week48,n=4242.4 ± 13.59
Hg,Year5,Week24,n=3902.9 ± 12.76
Hg,Year5,Week48,n=3623.2 ± 13.26
Hg,Year6,Week24,n=3062.7 ± 13.19
Hg,Year6,Week48,n=2822.3 ± 13.83
Hg,Year7,Week24,n=1812.9 ± 14.54
Hg,Year7,Week48,n=1304.0 ± 14.66
Hg,Year8,Week24,n=521.5 ± 14.84
Hg,Year8,Week48,n=13-0.2 ± 13.95
Hg,Year9,Week24,n=6-0.7 ± 20.67
Hg,Year9,Week48,n=1-29.0 ± NA
Hg,Exit,n=6193.2 ± 13.90
Hg,8 Week Follow up,n=5342.8 ± 13.71
PrimaryChange From Baseline in Hematocrit at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks). Change from Baseline in Hematocrit is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · Percentage of blood by volume
Change From Baseline in Hematocrit at the Indicated Time Points
Percentage of blood by volumeBelimumab 10mg/kg IV
Hematocrit,Year1,Week4,n=6970.01 ± 2.250
Hematocrit,Year1,Week12,n=6980.38 ± 2.729
Hematocrit,Year1,Week24,n=6990.75 ± 2.928
Hematocrit,Year1,Week36,n=6880.53 ± 2.954
Hematocrit,Year1,Week48,n=6860.35 ± 3.286
Hematocrit,Year2,Week24,n=6350.94 ± 3.427
Hematocrit,Year2,Week48,n=5910.78 ± 3.584
Hematocrit,Year3,Week24,n=5341.29 ± 3.828
Hematocrit,Year3,Week48,n=4781.39 ± 3.800
Hematocrit,Year4,Week24,n=4461.67 ± 3.834
Hematocrit,Year4,Week48,n=4241.15 ± 3.998
Hematocrit,Year5,Week24,n=3901.69 ± 3.776
Hematocrit,Year5,Week48,n=3621.98 ± 3.842
Hematocrit,Year6,Week24,n=3061.93 ± 3.939
Hematocrit,Year6,Week48,n=2822.07 ± 4.023
Hematocrit,Year7,Week24,n=1811.81 ± 4.251
Hematocrit,Year7,Week48,n=1302.11 ± 4.238
Hematocrit,Year8,Week24,n=521.42 ± 4.390
Hematocrit,Year8,Week48,n=131.48 ± 4.234
Hematocrit,Year9,Week24,n=62.03 ± 6.001
Hematocrit,Year9,Week48,n=1-6.00 ± NA
Hematocrit,Exit,n=6191.91 ± 4.202
Hematocrit,8 Week Follow up,n=5341.85 ± 4.077
PrimaryChange From Baseline in Erythrocytes (Eryth) at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 hematology parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Erythrocytes is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · Trillions cells per liter
Change From Baseline in Erythrocytes (Eryth) at the Indicated Time Points
Trillions cells per literBelimumab 10mg/kg IV
Eryth,Year1,Week4,n=697-0.00 ± 0.231
Eryth,Year1,Week12,n=6980.04 ± 0.280
Eryth,Year1,Week24,n=6990.06 ± 0.293
Eryth,Year1,Week36,n=6880.06 ± 0.299
Eryth,Year1,Week48,n=6860.06 ± 0.328
Eryth,Year2,Week24,n=6350.07 ± 0.335
Eryth,Year2,Week48,n=5910.04 ± 0.362
Eryth,Year3,Week24,n=5340.04 ± 0.364
Eryth,Year3,Week48,n=4780.05 ± 0.381
Eryth,Year4,Week24,n=4460.06 ± 0.372
Eryth,Year,Week48,n=4240.05 ± 0.379
Eryth,Year5,Week24,n=3900.09 ± 0.375
Eryth,Year5,Week48,n=3620.11 ± 0.383
Eryth,Year6,Week24,n=3060.12 ± 0.396
Eryth,Year6,Week48,n=2820.17 ± 0.408
Eryth,Year7,Week24,n=1810.17 ± 0.415
Eryth,Year7,Week48,n=1300.22 ± 0.387
Eryth,Year8,Week24,n=520.21 ± 0.375
Eryth,Year8,Week48,n=130.15 ± 0.207
Eryth,Year9,Week24,n=60.30 ± 0.374
Eryth,Year9,Week48,n=10.20 ± NA
Eryth,Exit,n=6190.14 ± 0.431
Eryth,8 Week Follow up,n=5340.13 ± 0.411
PrimaryChange From Baseline in Calcium (Ca), Carbon Dioxide (CO2), Chloride, Magnesium (Mg), Phosphate (Phos), Potassium (K), Sodium (Na) at the Indicated Time Points

Electrolytes parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 electrolytes parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Ca,CO2, Chloride, Mg, Phos, K and Na were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Calcium (Ca), Carbon Dioxide (CO2), Chloride, Magnesium (Mg), Phosphate (Phos), Potassium (K), Sodium (Na) at the Indicated Time Points
Millimoles per liter (mmol/L)Belimumab 10mg/kg IV
Ca,Year1,Week4,n=6970.0030 ± 0.0763
Ca,Year1,Week12,n=6960.0020 ± 0.0749
Ca,Year1,Week24,n=696-0.0035 ± 0.0750
Ca,Year1,Week36,n=6770.0024 ± 0.0836
Ca,Year1,Week48,n=687-0.0065 ± 0.0778
Ca,Year2,Week24,n=636-0.0075 ± 0.0764
Ca,Year2,Week48,n=587-0.0091 ± 0.0837
Ca,Year3,Week24,n=526-0.0047 ± 0.0810
Ca,Year3,Week48,n=481-0.0123 ± 0.0800
Ca,Year4,Week24,n=438-0.0056 ± 0.0771
Ca,Year,Week48,n=418-0.0193 ± 0.0805
Ca,Year5,Week24,n=387-0.0129 ± 0.0885
Ca,Year5,Week48,n=358-0.0140 ± 0.0919
Ca,Year6,Week24,n=303-0.0053 ± 0.0903
Ca,Year6,Week48,n=283-0.0146 ± 0.0870
Ca,Year7,Week24,n=182-0.0076 ± 0.0839
Ca,Year7,Week48,n=130-0.0079 ± 0.1172
Ca,Year8,Week24,n=510.0003 ± 0.0806
Ca,Year8,Week48,n=13-0.0395 ± 0.0611
Ca,Year9,Week24,n=6-0.0402 ± 0.0336
Ca,Year9,Week48,n=1-0.0642 ± NA
Ca,Exit,n=6190.0006 ± 0.0864
Ca,8 Week Follow up,n=534-0.0014 ± 0.0909
CO2,Year1,Week4,n=701-0.0 ± 2.77
CO2,Year1,Week12,n=700-0.1 ± 2.76
CO2,Year1,Week24,n=701-0.1 ± 2.73
CO2,Year1,Week36,n=6820.1 ± 2.73
CO2,Year1,Week48,n=692-0.1 ± 2.78
CO2,Year2,Week24,n=641-0.3 ± 2.94
CO2,Year2,Week48,n=692-0.3 ± 2.87
CO2,Year3,Week24,n=531-0.2 ± 2.90
CO2,Year3,Week48,n=486-0.4 ± 2.75
CO2,Year4,Week24,n=438-0.0 ± 2.76
CO2,Year4,Week48,n=418-0.5 ± 3.04
CO2,Year5,Week24,n=393-0.2 ± 2.90
CO2,Year5,Week48,n=361-0.8 ± 2.82
CO2,Year6,Week24,n=303-0.0 ± 2.86
CO2,Year6,Week48,n=284-0.5 ± 2.76
CO2,Year7,Week24,n=1820.2 ± 2.78
CO2,Year7,Week48,n=1300.2 ± 2.67
CO2,Year8,Week24,n=521.0 ± 2.78
CO2,Year8,Week48,n=130.4 ± 3.38
CO2,Year9,Week24,n=6-0.3 ± 0.82
CO2,Year9,Week48,n=1-3.0 ± NA
CO2,Exit,n=625-0.3 ± 3.00
CO2,8 week Follow up,n=538-0.2 ± 3.00
Chloride,Year1,Week4,n=7070.3 ± 2.33
Chloride,Year1,Week12,n=7040.6 ± 2.56
Chloride,Year1,Week24,n=7030.6 ± 2.42
Chloride,Year1,Week36,n=6840.6 ± 2.47
Chloride,Year1,Week48,n=6930.4 ± 2.44
Chloride,Year2,Week24,n=6430.5 ± 2.62
Chloride,Year2,Week48,n=5980.5 ± 2.81
Chloride,Year3,Week24,n=5350.7 ± 3.04
Chloride,Year3,Week48,n=4880.6 ± 2.73
Chloride,Year4,Week24,n=4390.5 ± 2.74
Chloride,Year4,Week48,n=4210.7 ± 2.84
Chloride,Year5,Week24,n=3920.6 ± 2.95
Chloride,Year5,Week48,n=3620.6 ± 2.77
Chloride,Year6,Week24,n=3041.0 ± 2.74
Chloride,Year6,Week48,n=2860.8 ± 2.67
Chloride,Year7,Week24,n=1830.7 ± 2.57
Chloride,Year7,Week48,n=1301.1 ± 2.73
Chloride,Year8,Week24,n=521.3 ± 2.86
Chloride,Year8,Week48,n=131.2 ± 3.54
Chloride,Year9,Week24,n=63.2 ± 1.47
Chloride,Year9,Week48,n=11.0 ± NA
Chloride,Exit,n=6240.4 ± 3.06
Chloride,8 Week Follow up,n=5380.4 ± 2.82
Mg,Year1,Week4,n=707-0.003 ± 0.0583
Mg,Year1,Week 12,n=705-0.006 ± 0.0647
Mg,Year1,Week 24,n=703-0.003 ± 0.0604
Mg,Year1,Week 36,n=684-0.004 ± 0.0616
Mg,Year1,Week 48,n=6930.002 ± 0.0597
Mg,Year2,Week 24,n=6430.002 ± 0.0694
Mg,Year2,Week 48,n=5980.001 ± 0.0711
Mg,Year3,Week 24,n=5350.010 ± 0.0668
Mg,Year3,Week 48,n=4880.010 ± 0.0669
Mg,Year4,Week 24,n=4390.016 ± 0.0700
Mg,Year4,Week 48,n=4210.017 ± 0.0709
Mg,Year 5,Week 24,n=3930.016 ± 0.0673
Mg,Year 5,Week 48,n=3620.021 ± 0.0688
Mg,Year 6,Week 24,n=3040.013 ± 0.0718
Mg,Year 6,Week 48,n=2860.011 ± 0.0639
Mg,Year 7,Week 24,n=1830.010 ± 0.0692
Mg,Year 7,Week 48,n=1300.013 ± 0.0635
Mg,Year 8,Week 24,n=520.025 ± 0.0702
Mg,Year 8,Week 48,n=130.042 ± 0.0685
Mg,Year 9,Week 24,n=60.030 ± 0.0613
Mg,Year 9,Week 48,n=10.040 ± NA
Mg, Exit,n=6250.022 ± 0.0738
Mg,8 Week Follow up,n=5390.021 ± 0.0729
Phos, Year1, Week4,n=7070.0102 ± 0.1908
Phos, Year1, Week12,n=7050.0004 ± 0.1999
Phos, Year1, Week24,n=703-0.0126 ± 0.1964
Phos, Year1, Week 36,n=6840.0101 ± 0.1976
Phos, Year1, Week48,n=693-0.0110 ± 0.2086
Phos, Year2, Week24,n=643-0.0026 ± 0.2138
Phos, Year2, Week48,n=598-0.0044 ± 0.2062
Phos, Year3, Week24,n=535-0.0109 ± 0.2028
Phos, Year3, Week48,n=488-0.0185 ± 0.2138
Phos, Year4, Week24,n=439-0.0072 ± 0.2067
Phos, Year4, Week48,n=421-0.0143 ± 0.2118
Phos, Year5, Week24,n=393-0.0199 ± 0.2751
Phos, Year5, Week48,n=362-0.0320 ± 0.2145
Phos, Year6, Week24,n=304-0.0238 ± 0.2214
Phos, Year6, Week48,n=286-0.0123 ± 0.2113
Phos, Year 7, Week 24,n=183-0.0196 ± 0.1970
Phos, Year 7, Week 48,n=130-0.0101 ± 0.1912
Phos, Year 8, Week 24,n=52-0.0041 ± 0.2038
Phos, Year 8, Week48,n=13-0.0340 ± 0.1337
Phos, Year9, Week 24,n=6-0.0803 ± 0.0823
Phos, Year 9, Week 48,n=10.0447 ± NA
Phos, Exit, n=625-0.0111 ± 0.2243
Phos, 8 Week Follow up,n=539-0.0034 ± 0.2233
K, Year 1, Week 4, n=7010.07 ± 0.411
K, Year 1, Week 12, n=7000.03 ± 0.380
K, Year 1, Week 24, n=7010.01 ± 0.377
K, Year 1, Week 36, n=6820.04 ± 0.387
K, Year 1, Week 48, n=6920.01 ± 0.377
K, Year 2, Week 24, n=6410.01 ± 0.393
K, Year 2, Week 48, n=5920.02 ± 0.372
K, Year 3, Week 24, n=5310.05 ± 0.401
K, Year 3, Week 48, n=4860.06 ± 0.421
K, Year 4, Week 24, n=4380.06 ± 0.408
K, Year 4, Week 48, n=4180.03 ± 0.397
K, Year 5, Week 24, n=3930.08 ± 0.427
K, Year 5, Week 48, n=3620.02 ± 0.404
K, Year 6, Week 24, n=3030.06 ± 0.429
K, Year 6, Week 48, n=2840.05 ± 0.437
K, Year 7, Week 24, n=1820.05 ± 0.445
K, Year 7, Week 48, n=1300.05 ± 0.413
K, Year 8, Week 24, n=52-0.02 ± 0.418
K, Year 8, Week 48, n=13-0.12 ± 0.300
K, Year 9, Week 24, n=60.05 ± 0.259
K, Year 9, Week 48, n=10.00 ± NA
K, Exit, n=6240.06 ± 0.435
K, 8 Week Follow up, n=5370.07 ± 0.452
Na, Year 1, Week 4, n=7070.1 ± 2.07
Na, Year 1, Week 12, n=7050.3 ± 2.25
Na, Year 1, Week 24, n=7030.4 ± 2.16
Na, Year 1, Week 36, n=6840.4 ± 2.10
Na, Year 1, Week 48, n=6930.1 ± 2.09
Na, Year 2, Week 24, n=643-0.0 ± 2.30
Na, Year 2, Week 48, n=5980.1 ± 2.63
Na, Year 3, Week 24, n=5350.2 ± 2.54
Na, Year 3, Week 48, n=4880.3 ± 2.36
Na, Year 4, Week 24, n=4390.1 ± 2.31
Na, Year 4, Week 48, n=4210.3 ± 2.36
Na, Year 5, Week 24, n=3930.3 ± 2.61
Na, Year 5, Week 48, n=3620.3 ± 2.18
Na, Year 6, Week 24, n=3040.3 ± 2.22
Na, Year 6, Week 48, n=2860.4 ± 2.44
Na, Year 7, Week 24, n=1830.1 ± 2.22
Na, Year 7, Week 48, n=1300.1 ± 2.38
Na, Year 8, Week 24, n=520.2 ± 2.67
Na, Year 8, Week 48, n=130.1 ± 2.14
Na, Year 9, Week 24, n=61.0 ± 1.79
Na, Year 9, Week 48, n=1-3.0 ± NA
Na, Exist, n=6240.1 ± 2.55
Na, 8 Week Follow up, n=5380.3 ± 2.36
PrimaryChange From Baseline in Blood Urea Nitrogen/Creatinine (BUN/Cr) at the Indicated Time Points

Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in BUN/Cr is summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · Ratio
Change From Baseline in Blood Urea Nitrogen/Creatinine (BUN/Cr) at the Indicated Time Points
RatioBelimumab 10mg/kg IV
BUN/Cr,Year1,Week4,n=707-0.2 ± 4.66
BUN/Cr,Year1,Week12,n=705-0.3 ± 4.88
BUN/CrYear1,Week24,n=703-0.7 ± 5.02
BUN/Cr,Year1,Week36,n=683-0.5 ± 5.61
BUN/Cr,Year1,Week48,n=693-0.2 ± 5.26
BUN/Cr,Year2,Week24,n=643-0.1 ± 5.68
BUN/Cr,Year2,Week48,n=5980.5 ± 5.55
BUN/Cr,Year3,Week24,n=5351.4 ± 5.48
BUN/Cr,Year3,Week48,n=4881.2 ± 5.92
BUN/Cr,Year4,Week24,n=4391.4 ± 5.65
BUN/Cr,Year 4,Week48,n=4211.0 ± 5.85
BUN/Cr,Year5,Week24,n=3930.7 ± 5.51
BUN/Cr,Year5,Week48,n=3621.0 ± 5.62
BUN/Cr,Year6,Week24,n=3041.0 ± 5.35
BUN/Cr,Year6,Week48,n=2861.3 ± 5.74
BUN/Cr,Year7,Week24,n=1830.8 ± 5.68
BUN/Cr,Year7,Week48,n=1301.2 ± 5.47
BUN/Cr,Year8,Week24,n=523.3 ± 4.64
BUN/Cr,Year8,Week48,n=133.5 ± 6.04
BUN/Cr,Year9,Week24,n=63.5 ± 3.08
BUN/Cr,Year9,Week48,n=11 ± 2.0
BUN/Cr,Exit,n=6250.9 ± 6.05
BUN/Cr,8 Week Follow up,n=5390.9 ± 5.91
PrimaryChange From Baseline in Albumin (Alb) and Protein (Pro) at the Indicated Time Points

Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Alb and Protein were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline in Albumin (Alb) and Protein (Pro) at the Indicated Time Points
Grams per liter (g/L)Belimumab 10mg/kg IV
Alb,Year1,Week4,n=707-0.1 ± 2.36
Alb,Year1,Week12,n=7050.2 ± 2.67
Alb,Year1,Week24,n=7030.6 ± 3.03
Alb,Year1,Week36,n=6840.7 ± 3.23
Alb,Year1,Week48,n=6931.2 ± 3.52
Alb,Year2,Week24,n=6431.2 ± 3.49
Alb,Year2,Week48,n=5981.2 ± 3.67
Alb,Year3,Week24,n=5351.2 ± 3.78
Alb,Year3,Week48,n=4881.4 ± 4.02
Alb,Year4,Week24,n=4391.7 ± 4.02
Alb,Year 4,Week48,n=4211.9 ± 4.04
Alb,Year5,Week24,n=3931.9 ± 3.85
Alb,Year5,Week48,n=3622.3 ± 3.89
Alb,Year6,Week24,n=3042.2 ± 3.78
Alb,Year6,Week48,n=2862.1 ± 4.07
Alb,Year7,Week24,n=1832.0 ± 3.60
Alb,Year7,Week48,n=1302.3 ± 3.92
Alb,Year8,Week24,n=521.9 ± 4.16
Alb,Year8,Week48,n=131.1 ± 4.11
Alb,Year9,Week24,n=60.7 ± 3.01
Alb,Year9,Week48,n=11.0 ± NA
Alb,Exit,n=6251.8 ± 4.74
Alb,8 Week Follow up,n=5391.7 ± 4.66
Pro,Year1,Week4,n=707-1.4 ± 3.81
Pro,Year1,Week12,n=705-2.0 ± 4.30
Pro,Year1,Week24,n=703-1.9 ± 4.68
Pro,Year1,Week36,n=684-2.3 ± 4.75
Pro,Year1,Week48,n=693-1.8 ± 4.94
Pro,Year2,Week24,n=643-2.3 ± 5.05
Pro,Year2,Week48,n=598-2.7 ± 5.53
Pro,Year3,Week24,n=535-3.1 ± 5.62
Pro,Year3,Week48,n=488-3.5 ± 5.91
Pro,Year4,Week24,n=439-3.2 ± 5.87
Pro,Year 4,Week48,n=421-3.2 ± 6.07
Pro,Year5,Week24,n=393-3.5 ± 5.75
Pro,Year5,Week48,n=362-3.6 ± 5.78
Pro,Year6,Week24,n=304-3.9 ± 5.57
Pro,Year6,Week48,n=286-4.0 ± 5.79
Pro,Year7,Week24,n=183-4.3 ± 5.36
Pro,Year7,Week48,n=130-3.9 ± 5.32
Pro,Year8,Week24,n=52-5.1 ± 6.38
Pro,Year8,Week48,n=13-4.8 ± 5.02
Pro,Year9,Week24,n=6-7.7 ± 7.03
Pro,Year9,Week48,n=10.0 ± NA
Pro,Exit,n=625-3.4 ± 6.45
Pro,8 Week Follow up,n=539-3.7 ± 6.42
PrimaryChange From Baseline in BUN and Glucose at the Indicated Time Points

Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in BUN and Glucose were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · mmol/L
Change From Baseline in BUN and Glucose at the Indicated Time Points
mmol/LBelimumab 10mg/kg IV
BUN,Year1,Week4,n=7070.0299 ± 1.6783
BUN,Year1,Week12,n=7050.0402 ± 1.9768
BUN,Year1,Week24,n=703-0.1443 ± 1.3723
BUN,Year1,Week36,n=683-0.0592 ± 1.6916
BUN,Year1,Week48,n=693-0.0406 ± 1.5541
BUN,Year2,Week24,n=643-0.0760 ± 1.6652
BUN,Year2,Week48,n=5980.0631 ± 1.6429
BUN,Year3,Week24,n=5350.0524 ± 1.6850
BUN,Year3,Week48,n=488-0.1013 ± 1.6910
BUN,Year4,Week24,n=4390.0967 ± 1.9398
BUN,Year 4,Week48,n=4210.0672 ± 2.1393
BUN,Year5,Week24,n=393-0.0291 ± 2.0169
BUN,Year5,Week48,n=3620.0899 ± 2.0903
BUN,Year6,Week24,n=3040.0959 ± 1.9852
BUN,Year6,Week48,n=2860.2325 ± 2.2724
BUN,Year7,Week24,n=183-0.0026 ± 1.6623
BUN,Year7,Week48,n=1300.1455 ± 1.7145
BUN,Year8,Week24,n=520.5458 ± 1.7299
BUN,Year8,Week48,n=130.3883 ± 1.4603
BUN,Year9,Week24,n=60.1648 ± 1.0466
BUN,Year9,Week48,n=10.5700 ± NA
BUN,Exit,n=6250.2448 ± 2.4618
BUN,8 Week Follow up,n=5390.0822 ± 2.5567
Glucose,Year1,Week4,n=707-0.0031 ± 1.0221
Glucose,Year1,Week12,n=7050.0333 ± 1.0627
Glucose,Year1,Week24,n=702-0.0396 ± 1.2656
Glucose,Year1,Week36,n=6840.0099 ± 1.0269
Glucose,Year1,Week48,n=6930.0010 ± 1.1726
Glucose,Year2,Week24,n=6430.0143 ± 1.3227
Glucose,Year2,Week48,n=598-0.0082 ± 1.1352
Glucose,Year3,Week24,n=535-0.0159 ± 1.3222
Glucose,Year3,Week48,n=4880.0309 ± 1.1841
Glucose,Year4,Week24,n=439-0.0160 ± 1.2213
Glucose,Year 4,Week48,n=421-0.0259 ± 1.1936
Glucose,Year5,Week24,n=3930.0554 ± 1.1255
Glucose,Year5,Week48,n=3620.0655 ± 1.2946
Glucose,Year6,Week24,n=3030.1290 ± 1.1163
Glucose,Year6,Week48,n=2860.2001 ± 1.2411
Glucose,Year7,Week24,n=1830.2303 ± 1.0514
Glucose,Year7,Week48,n=1300.2335 ± 0.8346
Glucose,Year8,Week24,n=520.3301 ± 0.9052
Glucose,Year8,Week48,n=130.1431 ± 0.8115
Glucose,Year9,Week24,n=60.2128 ± 0.4914
Glucose,Year9,Week48,n=10.4739 ± NA
Glucose,Exit,n=6240.1842 ± 1.8723
Glucose,8 Week Follow up,n=5390.0338 ± 1.4139
PrimaryChange From Baseline in Creatinine (Cr) and Urate at the Indicated Time Points

Other chemistries parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 other chemistries were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Cr and Urate were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · Micromoles per liter (µmol/L)
Change From Baseline in Creatinine (Cr) and Urate at the Indicated Time Points
Micromoles per liter (µmol/L)Belimumab 10mg/kg IV
Urate,Year1,Week4,n=7071.0332 ± 45.8504
Urate,Year1,Week12,n=7040.4089 ± 54.3182
Urate,Year1,Week24,n=703-0.0510 ± 49.2328
Urate,Year1,Week36,n=6840.6713 ± 50.7341
Urate,Year1,Week48,n=693-1.5147 ± 50.5928
Urate,Year2,Week24,n=6432.7246 ± 55.7467
Urate,Year2,Week48,n=5984.1255 ± 60.0251
Urate,Year3,Week24,n=5356.7497 ± 60.4118
Urate,Year3,Week48,n=4886.9744 ± 63.6876
Urate,Year4,Week24,n=4395.9658 ± 66.6167
Urate,Year 4,Week48,n=4214.0772 ± 67.9587
Urate,Year5,Week24,n=393-0.5634 ± 66.9130
Urate,Year5,Week48,n=362-0.8979 ± 67.3843
Urate,Year6,Week24,n=3042.9530 ± 62.3168
Urate,Year6,Week48,n=2861.1244 ± 67.3175
Urate,Year7,Week24,n=1832.1521 ± 53.0854
Urate,Year7,Week48,n=1304.0062 ± 58.3577
Urate,Year8,Week24,n=52-1.1003 ± 51.8840
Urate,Year8,Week48,n=1329.2043 ± 80.1811
Urate,Year9,Week24,n=60.2187 ± 45.1947
Urate,Year9,Week48,n=1-69.6640 ± NA
Urate,Exit,n=6251.6479 ± 74.4078
Urate,8 Week Follow up,n=539-2.7404 ± 75.5887
Cr,Year1,Week4,n=7070.913 ± 14.2222
Cr,Year1,Week12,n=7050.751 ± 14.0933
Cr,Year1,Week24,n=7030.823 ± 9.5372
Cr,Year1,Week36,n=6841.313 ± 13.1107
Cr,Year1,Week48,n=6930.439 ± 11.1364
Cr,Year2,Week24,n=643-0.217 ± 13.9502
Cr,Year2,Week48,n=598-0.922 ± 13.6541
Cr,Year3,Week24,n=535-3.870 ± 17.8146
Cr,Year3,Week48,n=488-4.844 ± 17.7059
Crea,Year4,Week24,n=439-3.196 ± 22.2874
Crea,Year 4,Week48,n=421-2.145 ± 30.9370
Cr,Year5,Week24,n=393-1.999 ± 32.6689
Cr,Year5,Week48,n=362-1.918 ± 28.8788
Cr,Year6,Week24,n=304-2.125 ± 24.2374
Cr,Year6,Week48,n=286-1.534 ± 28.8012
Cr,Year7,Week24,n=183-2.511 ± 15.6881
Cr,Year7,Week48,n=130-2.586 ± 14.0864
Cr,Year8,Week24,n=52-4.659 ± 16.3056
Cr,Year8,Week48,n=13-6.175 ± 6.6311
Cr,Year9,Week24,n=6-8.933 ± 5.6925
Cr,Year9,Week48,n=10.040 ± NA
Cr,Exit,n=6240.606 ± 35.9813
Cr,8 Week Follow up,n=539-1.108 ± 39.0635
PrimaryChange From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels

Liver function parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 liver function parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in ALT, ALP, AST, GGT and LDH were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · International Units/liter (IU/L)
Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Levels
International Units/liter (IU/L)Belimumab 10mg/kg IV
ALT, Year 1 Week 4, n=707-0.4 ± 10.18
ALT, Year 1 Week 12, n=705-0.9 ± 12.31
ALT, Year 1 Week 24, n=703-0.9 ± 19.46
ALT, Year 1 Week 36, n=684-1.0 ± 15.61
ALT, Year 1 Week 48, n=693-0.7 ± 15.04
ALT, Year 2 Week 24, n=6430.2 ± 23.56
ALT, Year 2 Week 48, n=5982.7 ± 57.67
ALT, Year 3 Week 24, n=535-1.3 ± 14.40
ALT, Year 3 Week 48, n=4880.1 ± 21.21
ALT, Year 4 Week 24, n=439-0.1 ± 18.72
ALT, Year 4 Week 48, n=421-0.6 ± 17.59
ALT, Year 5 Week 24, n=393-1.3 ± 18.74
ALT, Year 5 Week 48, n=362-0.4 ± 22.72
ALT, Year 6 Week 24, n=304-0.2 ± 20.54
ALT, Year 6 Week 48, n=2860.9 ± 20.94
ALT, Year 7 Week 24, n=1831.3 ± 19.46
ALT, Year 7 Week 48, n=130-0.1 ± 16.79
ALT, Year 8 Week 24, n=522.7 ± 31.15
ALT, Year 8 Week 48, n=135.8 ± 33.54
ALT, Year 9 Week 24, n=69.3 ± 27.77
ALT, Year 9 Week 48, n=1-6.0 ± NA
ALT, Exit, n=624-0.6 ± 17.03
ALT, 8 Week follow-up, n=539-0.8 ± 17.06
ALP, Year 1 Week 4, n=7070.0 ± 11.85
ALP, Year 1 Week 12, n=7050.5 ± 13.31
ALP, Year 1 Week 24, n=7032.1 ± 17.76
ALP, Year 1 Week 36, n=6841.7 ± 22.81
ALP, Year 1 Week 48, n=6934.6 ± 21.18
ALP, Year 2 Week 24, n=6435.1 ± 21.58
ALP, Year 2 Week 48, n=5986.1 ± 23.23
ALP, Year 3 Week 24, n=5355.9 ± 18.95
ALP, Year 3 Week 48, n=4887.3 ± 22.22
ALP, Year 4 Week 24, n=4397.2 ± 21.56
ALP, Year 4 Week 48, n=4218.1 ± 27.35
ALP, Year 5 Week 24, n=3937.2 ± 21.01
ALP, Year 5 Week 48, n=3628.5 ± 20.61
ALP, Year 6 Week 24, n=3049.4 ± 23.28
ALP, Year 6 Week 48, n=28611.5 ± 27.39
ALP, Year 7 Week 24, n=18310.9 ± 28.08
ALP, Year 7 Week 48, n=1307.5 ± 22.50
ALP, Year 8 Week 24, n=5212.9 ± 26.64
ALP, Year 8 Week 48, n=136.1 ± 30.04
ALP, Year 9 Week 24, n=64.2 ± 35.43
ALP, Year 9 Week 48, n=112.0 ± NA
ALP, Exit, n=6257.5 ± 25.35
ALP, 8 Week follow-up, n=5396.1 ± 23.00
AST, Year 1 Week 4, n=701-0.6 ± 10.56
AST, Year 1 Week 12, n=700-1.3 ± 14.12
AST, Year 1 Week 24, n=701-1.0 ± 20.79
AST, Year 1 Week 36, n=682-1.0 ± 17.88
AST, Year 1 Week 48, n=692-0.9 ± 14.38
AST, Year 2 Week 24, n=641-0.4 ± 22.22
AST, Year 2 Week 48, n=5922.9 ± 57.25
AST, Year 3 Week 24, n=531-1.4 ± 13.26
AST, Year 3 Week 48, n=486-0.5 ± 17.23
AST, Year 4 Week 24, n=438-0.9 ± 14.60
AST, Year 4 Week 48, n=418-0.7 ± 15.32
AST, Year 5 Week 24, n=393-1.3 ± 16.07
AST, Year 5 Week 48, n=362-0.8 ± 18.57
AST, Year 6 Week 24, n=303-0.5 ± 16.95
AST, Year 6 Week 48, n=284-0.2 ± 19.00
AST, Year 7 Week 24, n=1820.6 ± 13.43
AST, Year 7 Week 48, n=130-0.3 ± 10.78
AST, Year 8 Week 24, n=523.0 ± 33.93
AST, Year 8 Week 48, n=135.8 ± 24.01
AST, Year 9 Week 24, n=67.7 ± 19.63
AST, Year 9 Week 48, n=10.0 ± NA
AST, Exit, n=625-0.6 ± 18.88
AST, 8 Week follow-up, n=539-1.1 ± 16.58
GGT, Year 1 Week 4, n=707-0.4 ± 23.39
GGT, Year 1 Week 12, n=705-1.4 ± 23.12
GGT, Year 1 Week 24, n=703-0.2 ± 39.50
GGT, Year 1 Week 36, n=6841.0 ± 64.60
GGT, Year 1 Week 48, n=6930.9 ± 35.99
GGT, Year 2 Week 24, n=643-0.7 ± 34.81
GGT, Year 2 Week 48, n=5980.1 ± 34.63
GGT, Year 3 Week 24, n=535-1.6 ± 33.88
GGT, Year 3 Week 48, n=4881.7 ± 45.42
GGT, Year 4 Week 24, n=4390.1 ± 39.13
GGT, Year 4 Week 48, n=4211.1 ± 54.41
GGT, Year 5 Week 24, n=393-2.0 ± 37.17
GGT, Year 5 Week 48, n=362-0.7 ± 43.39
GGT, Year 6 Week 24, n=304-1.0 ± 42.04
GGT, Year 6 Week 48, n=2861.3 ± 41.84
GGT, Year 7 Week 24, n=1831.8 ± 37.06
GGT, Year 7 Week 48, n=130-1.0 ± 27.86
GGT, Year 8 Week 24, n=522.7 ± 39.90
GGT, Year 8 Week 48, n=13-0.3 ± 27.97
GGT, Year 9 Week 24, n=613.3 ± 26.96
GGT, Year 9 Week 48, n=1-7.0 ± NA
GGT, Exit, n=6250.7 ± 41.40
GGT, 8 Week follow-up, n=5390.2 ± 39.22
LDH, Year 1 Week 4, n=701-4.1 ± 77.93
LDH, Year 1 Week 12, n=700-6.0 ± 80.55
LDH, Year 1 Week 24, n=701-6.6 ± 80.09
LDH, Year 1 Week 36, n=682-8.8 ± 80.05
LDH, Year 1 Week 48, n=692-7.3 ± 81.32
LDH, Year 2 Week 24, n=641-9.4 ± 85.83
LDH, Year 2 Week 48, n=592-9.6 ± 95.52
LDH, Year 3 Week 24, n=532-11.8 ± 93.90
LDH, Year 3 Week 48, n=486-15.1 ± 94.65
LDH, Year 4 Week 24, n=438-16.5 ± 99.93
LDH, Year 4 Week 48, n=418-16.9 ± 102.11
LDH, Year 5 Week 24, n=393-17.5 ± 106.45
LDH, Year 5 Week 48, n=362-19.8 ± 108.33
LDH, Year 6 Week 24, n=303-21.7 ± 115.77
LDH, Year 6 Week 48, n=284-21.3 ± 122.62
LDH, Year 7 Week 24, n=182-15.2 ± 44.05
LDH, Year 7 Week 48, n=130-16.3 ± 42.51
LDH, Year 8 Week 24, n=52-14.3 ± 40.14
LDH, Year 8 Week 48, n=13-31.5 ± 53.04
LDH, Year 9 Week 24, n=6-27.2 ± 32.64
LDH, Year 9 Week 48, n=1-65.0 ± NA
LDH, Exit, n=624-13.1 ± 90.39
LDH, 8 Week follow-up, n=538-12.7 ± 95.65
PrimaryChange From Baseline in Bilirubin (Bili) Levels

Liver function parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 liver function parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Bili were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · µmol/L
Change From Baseline in Bilirubin (Bili) Levels
µmol/LBelimumab 10mg/kg IV
Year 1 Week 4, n=7070.142 ± 2.8398
Year 1 Week 12, n=7050.008 ± 2.6383
Year 1 Week 24, n=7030.217 ± 3.1280
Year 1 Week 36, n=6840.173 ± 2.7566
Year 1 Week 48, n=6930.367 ± 2.8441
Year 2 Week 24, n=6430.488 ± 2.9346
Year 2 Week 48, n=5980.540 ± 3.2181
Year 3 Week 24, n=5350.606 ± 3.1612
Year 3 Week 48, n=4880.637 ± 3.2474
Year 4 Week 24, n=4390.548 ± 2.9773
Year 4 Week 48, n=4210.629 ± 3.4680
Year 5 Week 24, n=3930.410 ± 2.6931
Year 5 Week 48, n=3620.788 ± 3.1324
Year 6 Week 24, n=3040.801 ± 2.9946
Year 6 Week 48, n=2850.638 ± 3.0669
Year 7 Week 24, n=1830.938 ± 2.8158
Year 7 Week 48, n=1301.129 ± 3.0314
Year 8 Week 24, n=521.280 ± 3.0707
Year 8 Week 48, n=130.768 ± 3.0434
Year 9 Week 24, n=60.028 ± 2.0182
Year 9 Week 48, n=1-2.870 ± NA
Exit, n=6240.573 ± 3.3274
8 Week follow-up, n=5390.572 ± 3.1052
PrimaryChange From Baseline in Immunoglobulin G (IgG) Levels

Immunoglobulin (Ig) parameters were assessed at Baseline, Week 4,12,24,36, and 48 during Year 1. From Year 2-9 Ig parameters were assessed at Week 24 and 48 ; Exit visit and at follow-up (up to 8 weeks post infusion). Change from Baseline in Ig G were summarized. The Baseline is defined as For Year 1, Day 0 values for MITT participants who were treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants who were treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed. NA indicates standard deviation was not calculable for a single data point.

Time frame:
Baseline and up to 9 years
Reported as:
Mean · g/L
Change From Baseline in Immunoglobulin G (IgG) Levels
g/LBelimumab 10mg/kg IV
Year 1 Week 12, n=213-1.571 ± 2.2970
Year 1 Week 24, n=709-1.963 ± 2.7334
Year 1 Week 48, n=695-2.507 ± 3.1054
Year 2 Week 24, n=482-3.058 ± 3.6147
Year 2 Week 48, n=605-3.232 ± 3.7414
Year 3 Week 24, n=143-3.453 ± 3.7073
Year 3 Week 48, n=405-3.791 ± 4.0450
Year 4 Week 24, n=146-3.839 ± 4.1411
Year 4 Week 48, n=362-3.794 ± 3.8780
Year 5 Week 24, n=111-4.356 ± 3.6399
Year 5 Week 48, n=322-4.323 ± 4.0169
Year 6 Week 24, n=71-5.111 ± 3.8846
Year 6 Week 48, n=268-4.697 ± 3.9599
Year 7 Week 24, n=50-4.803 ± 3.5908
Year 7 Week 48, n=115-4.982 ± 4.0769
Year 8 Week 24, n=18-6.016 ± 3.8450
Year 8 Week 48, n=12-5.520 ± 5.1564
Year 9 Week 48, n=10.710 ± NA
Exit, n=627-4.138 ± 4.0025
8 Week Follow up, n=543-4.325 ± 4.0246
PrimaryNumber of Participants With Immunogenic Response by Year

Immunogenic response was analyzed using serum samples for anti-belimumab antibody measurements in MITT population. Categories of response are Negative, Transient Positive (+) means single + response that does not occur at the final assessment, and Persistent + means + response that occurs at least 2 consecutive assessments or a single result at the final assessment. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to 9 years
Reported as:
Number · Participants
Number of Participants With Immunogenic Response by Year
ParticipantsBelimumab 10mg/kg IV
Year 0-1 Negative, n=717707
Year 1-2 Negative, n=684656
Year 2-3 Negative, n=590577
Year 3-4, Negative, n=502498
Year 4-5 Negative, n=432432
Year 5-6 Negative, n=336336
Year 6-7 Negative, n=212212
Year 7-8 Negative, n=6464
Year 8 plus Negative, n=66
Year 0-1 Transient +, n=71710
Year 1-2 Transient + n=68418
Year 2-3 Transient +, n=5909
Year 3-4 Transient +, n=5024
Year 4-5 Transient +, n=4320
Year 5-6 Transient +, n=3360
Year 6-7 Transient +, n=2120
Year 7-8 Transient +, n=640
Year 8 plus Transient +, n=60
Year 0-1 Persistent+,n=7170
Year 1-2 Persistent+,n=68410
Year 2-3 Persistent+,n=5903
Year 3-4 Persistent+,n=5020
Year 4-5 Persistent+,n=4320
Year 5-6 Persistent+,n=3360
Year 6-7 Persistent+,n=2120
Year 7-8 Persistent+,n=640
Year 8 plus Persistent+,n=60
Year 0-1 Unknown, n=7170
Year 1-2 Unknown, n=6840
Year 2-3 Unknown, n=5901
Year 3-4 Unknown, n=5020
Year 4-5 Unknown, n=4320
Year 5-6 Unknown, n=3360
Year 6-7 Unknown, n=2120
Year 7-8 Unknown, n=640
Year 8 plus Unknown, n=60
PrimaryNumber of Participants With IgG Values Below the Lower Limit of Normal by Year

Blood samples were collected to evaluate IgG levels at Baseline and at Weeks 12, 24 and 48 during Year 1. From Year 2-9, IgG was evaluated at Week 24 and 48 ; Exit visit and at follow-up visit (up to 8 weeks post last infusion). Number of participants with IgG immunoglobulin values below the LLN at each one year interval are presented. Baseline includes Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. If a participant had more than one response within a year, then the last response within the year interval (usually the Week 48 assessment) was summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to 9 years
Reported as:
Number · Participants
Number of Participants With IgG Values Below the Lower Limit of Normal by Year
ParticipantsBelimumab 10mg/kg IV
Baseline, n=7356
Any Time Post Baseline, n=73564
Year 0-1, n=73522
Year 1-2, n=70124
Year 2-3, n=62022
Year 3-4, n=51419
Year 4-5, n=44215
Year 5-6, n=34510
Year 6-7, n=2198
Year 7-8, n=652
More than 8 Years, n=60
PrimaryNumber of Participants With Shifts From Baseline in Prednisone and Other Steroids Dose by Visit

Participants who had improving SLE disease activity for at least 8 weeks, at the investigator's discretion, the steroid dose was reduced by reduction to 7.5 mg/day. If the participant continued to have stable or improving disease activity after 4 weeks on a reduced dose, then the investigator considered reducing the dose again. Baseline includes extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. Number of participants with shifts from Baseline total daily dose category by visit is summarized.

Time frame:
Up to 9 years
Reported as:
Number · Participants
Number of Participants With Shifts From Baseline in Prednisone and Other Steroids Dose by Visit
ParticipantsParticipants With no Prednisone and Other Steroids at BaselineParticipants With Baseline Daily Dose of >0 to <=7.5 mgParticipants With Baseline Daily Dose of >7.5 to <=40 mgParticipants With Baseline Daily Dose of >40 mg
Total daily dose=0, Year 1, Week 2440510
Total daily dose >0 to <=7.5, Year 1, Week 241194710
Total daily dose >7.5 to <=40, Year 1, Week 242183761
Total daily dose >40, Year 1, Week 240010
Total daily dose=0, Year 1, Week 484013130
Total daily dose >0 to <=7.5, Year 1, Week 4821801230
Total daily dose >7.5 to <=40, Year 1, Week 480193011
Total daily dose >40, Year 1, Week 481040
Total daily dose=0, Year 2, Week 243919200
Total daily dose >0 to <=7.5, Year 2, Week 2431571450
Total daily dose >7.5 to <=40, Year 2, Week 240252371
Total daily dose >40, Year 2, Week 240050
Total daily dose=0, Year 2, Week 483624210
Total daily dose >0 to <=7.5, Year 2, Week 4811431630
Total daily dose >7.5 to <=40, Year 2, Week 481261951
Total daily dose >40, Year 2, Week 480010
Total daily dose=0, Year 3, Week 243319250
Total daily dose >0 to <=7.5, Year 3, Week 2431301590
Total daily dose >7.5 to <=40, Year 3, Week 241271571
Total daily dose >40, Year 3, Week 240000
Total daily dose=0, Year 3, Week 483120300
Total daily dose >0 to <=7.5, Year 3, Week 4831221270
Total daily dose >7.5 to <=40, Year 3, Week 480231451
Total daily dose >40, Year 3, Week 480020
Total daily dose=0, Year 4, Week 242817340
Total daily dose >0 to <=7.5, Year 4, Week 2431101340
Total daily dose >7.5 to <=40, Year 4, Week 242231201
Total daily dose >40, Year 4, Week 240020
Total daily dose=0, Year 4, Week 482218400
Total daily dose >0 to <=7.5, Year 4, Week 4831001291
Total daily dose >7.5 to <=40, Year 4, Week 481161080
Total daily dose >40, Year 4, Week 480100
Total daily dose=0, Year 5, Week 241928330
Total daily dose >0 to <=7.5, Year 5, Week 243841241
Total daily dose >7.5 to <=40, Year 5, Week 24116990
Total daily dose >40, Year 5, Week 240020
Total daily dose=0, Year 5, Week 481726340
Total daily dose >0 to <=7.5, Year 5, Week 481751191
Total daily dose >7.5 to <=40, Year 5, Week 48113850
Total daily dose >40, Year 5, Week 480000
Total daily dose=0, Year 6, Week 241025330
Total daily dose >0 to <=7.5, Year 6, Week 24262991
Total daily dose >7.5 to <=40, Year 6, Week 24010760
Total daily dose >40, Year 6, Week 240020
Total daily dose=0, Year 6, Week 481024350
Total daily dose >0 to <=7.5, Year 6, Week 48154901
Total daily dose >7.5 to <=40, Year 6, Week 48011680
Total daily dose >40, Year 6, Week 480000
Total daily dose=0, Year 7, Week 24410290
Total daily dose >0 to <=7.5, Year 7, Week 24041641
Total daily dose >7.5 to <=40, Year 7, Week 2413400
Total daily dose >40, Year 7, Week 240000
Total daily dose=0, Year 7, Week 4843240
Total daily dose >0 to <=7.5, Year 7, Week 48032341
Total daily dose >7.5 to <=40, Year 7, Week 4806290
Total daily dose >40, Year 7, Week 480000
Total daily dose=0, Year 8, Week 242180
Total daily dose >0 to <=7.5, Year 8, Week 24013151
Total daily dose >7.5 to <=40, Year 8, Week 2402110
Total daily dose >40, Year 8, Week 240000
Total daily dose=0, Year 8, Week 481050
Total daily dose >0 to <=7.5, Year 8, Week 480360
Total daily dose >7.5 to <=40, Year 8, Week 480210
Total daily dose >40, Year 8, Week 480000
Total daily dose=0, Year 9, Week 240010
Total daily dose >0 to <=7.5, Year 9, Week 240130
Total daily dose >7.5 to <=40, Year 9, Week 240100
Total daily dose >40, Year 9, Week 240000
Total daily dose=0, Year 9, Week 480000
Total daily dose >0 to <=7.5, Year 9, Week 480140
Total daily dose >7.5 to <=40, Year 9, Week 480100
Total daily dose >40, Year 9, Week 480000
PrimaryNumber of Participants With Any SLICC/ ACR Damage Index Worsening (Change > 0) From Baseline by Visit

The SLICC/ACR Damage Index was assessed every 48 weeks and at the exit visit as a measure of disease activity. It was developed to assess the accumulated damage since the onset of the disease. The number of participants with worsening in their SLICC/ACR Damage Index score compared with Baseline have been presented. Worsening was defined as a change in score (post-Baseline visit score - Baseline score) \> 0. Baseline includes extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with Belimumab in the parent study. For years in which a participant was withdrawn from the study, the exit visit assessment was used in place of the Week 48 assessment for the year. This value was not carried forward through later years. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.

Time frame:
Up to 9 years
Reported as:
Number · Participants
Number of Participants With Any SLICC/ ACR Damage Index Worsening (Change > 0) From Baseline by Visit
ParticipantsBelimumab 10mg/kg IV
Year 1,Week 48, n=71639
Year 2,Week 48, n=66750
Year 3,Week 48, n=58056
Year 4,Week 48, n=48857
Year 5,Week 48, n=42351
Year 6,Week 48, n=33041
Year 7,Week 48, n=21328
Year 8,Week 48, n=658
Year 9,Week 48, n=60

Adverse events

Collected over On-treatment SAEs and non-serious adverse events (AEs) were collected from the start of investigational product and until 8 Weeks after the last infusion of trial medication (Approximately 8 years plus). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab 10mg/kg IV11/735 (1.5%)231/735 (31.4%)614/735 (83.5%)
Most frequent serious events
Showing 10 of 276
Most frequent serious events
EventBelimumab 10mg/kg IV
Pneumonia bacterialInfections and infestations14/735
CellulitisInfections and infestations12/735
Lupus nephritisRenal and urinary disorders12/735
PyrexiaGeneral disorders9/735
Urinary tract infectionInfections and infestations9/735
Urinary tract infection bacterialInfections and infestations9/735
LeukopeniaBlood and lymphatic system disorders8/735
PneumoniaInfections and infestations8/735
AnaemiaBlood and lymphatic system disorders7/735
AppendicitisInfections and infestations6/735
Most frequent other events
Showing 10 of 40
Most frequent other events
EventBelimumab 10mg/kg IV
HeadacheNervous system disorders205/735
NasopharyngitisInfections and infestations155/735
DiarrhoeaGastrointestinal disorders143/735
ArthralgiaMusculoskeletal and connective tissue disorders134/735
InfluenzaInfections and infestations132/735
CoughRespiratory, thoracic and mediastinal disorders120/735
Back painMusculoskeletal and connective tissue disorders102/735
Urinary tract infection bacterialInfections and infestations87/735
Viral upper respiratory tract infectionInfections and infestations84/735
Upper respiratory tract infectionInfections and infestations82/735

Baseline characteristics

Modified Intention to Treat (MITT) includes all participants who were enrolled in BEL112234 and were treated with at least one dose of belimumab in the continuation study.

Age, Continuous
Age, Continuous(Years)Belimumab 10mg/kg IV
Mean37.2 ± 11.17
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab 10mg/kg IV
Female695
Male40
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belimumab 10mg/kg IV
Black or African American/African Heritage18
American Indian or Alaska Native225
East Asian Heritage118
South Asian Heritage38
Southeast Asian Heritage58
Middle East/North African Heritage22
White/Caucasian/European Heritage256
08

Study locations

110 sites
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1015, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1419AHN, Argentina
  • GSK Investigational Site
    La Plata, Buenos Aires B1904CFH,, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe 2000, Argentina
  • GSK Investigational Site
    San Miguel de Tucuman, Tucumán T4000AXL, Argentina
  • GSK Investigational Site
    Buenos Aires, C1280AEB, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1426AAL, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1417EYG, Argentina
  • GSK Investigational Site
    Vienna, A-1100, Austria
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Salvador, Bahía 40.150-410, Brazil
  • GSK Investigational Site
    Goiania, Goiás 74110-120, Brazil
  • GSK Investigational Site
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • GSK Investigational Site
    Recife, Pernambuco 50670-420, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90610000, Brazil
  • GSK Investigational Site
    Sao Paulo, São Paulo 04039-901, Brazil
  • GSK Investigational Site
    Campinas, 13083-888, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 22411-001, Brazil
  • GSK Investigational Site
    São Paulo, 04032-060, Brazil
  • GSK Investigational Site
    São Paulo, 04266-010, Brazil
  • GSK Investigational Site
    Toronto, Ontario M5T 2S8, Canada
  • GSK Investigational Site
    Montreal, Quebec H3G 1A4, Canada
  • GSK Investigational Site
    Viña del Mar, Valparaíso 2570017, Chile
  • GSK Investigational Site
    Santiago, 8431657, Chile
  • GSK Investigational Site
    Barranquilla, Colombia
  • GSK Investigational Site
    Bogota, Colombia
  • GSK Investigational Site
    Bucaramanga, Colombia
  • GSK Investigational Site
    Medellin, Colombia
  • GSK Investigational Site
    Brno - Bohunice, 625 00, Czechia
  • GSK Investigational Site
    Hradec Králové, 500 05, Czechia
  • GSK Investigational Site
    Olomouc, 775 20, Czechia
  • GSK Investigational Site
    Praha 2, 128 50, Czechia
  • GSK Investigational Site
    Suresnes, 92150, France
  • GSK Investigational Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • GSK Investigational Site
    Erlangen, Bayern 91054, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60590, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04103, Germany
  • GSK Investigational Site
    Jena, Thueringen 07743, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 14059, Germany
  • GSK Investigational Site
    Kiel, 24105, Germany
  • GSK Investigational Site
    Chai Wan, Hong Kong
  • GSK Investigational Site
    New Territories, Hong Kong
  • GSK Investigational Site
    Bangalore, 560034, India
  • GSK Investigational Site
    Hyderabad, Andhra Pradesh, 500482, India
  • GSK Investigational Site
    Lucknow, 226003, India
  • GSK Investigational Site
    Secunderabad, 500003, India
  • GSK Investigational Site
    Trivandrum, 695029, India
  • GSK Investigational Site
    Beer Sheva, 84101, Israel
  • GSK Investigational Site
    Haifa, 31048, Israel
  • GSK Investigational Site
    Haifa, 31096, Israel
  • GSK Investigational Site
    Haifa, 34362, Israel
  • GSK Investigational Site
    Petach Tikva, 49100, Israel
  • GSK Investigational Site
    Ramat-Gan, 52621, Israel
  • GSK Investigational Site
    Rehovot, 76100, Israel
  • GSK Investigational Site
    Roma, 00152, Italy
  • GSK Investigational Site
    Busan, 602-715, Korea, Republic of
  • GSK Investigational Site
    Daejeon, 302-799, Korea, Republic of
  • GSK Investigational Site
    Incheon, 400-711, Korea, Republic of
  • GSK Investigational Site
    Pusan, 602-739, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, Korea, Republic of
  • GSK Investigational Site
    Suwon, Kyonggi-do, 443-721, Korea, Republic of
  • GSK Investigational Site
    Guadalajara, Jalisco 44160, Mexico
  • GSK Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • GSK Investigational Site
    Mexico, 7760, Mexico
  • GSK Investigational Site
    San Luis Potosí, 78240, Mexico
  • GSK Investigational Site
    Maastricht, 6229 HX, Netherlands
  • GSK Investigational Site
    Rotterdam, 3015 CE, Netherlands
  • GSK Investigational Site
    Rotterdam, 3083 AN, Netherlands
  • GSK Investigational Site
    Surco, Lima, Peru
  • GSK Investigational Site
    Callao, Callao 2, Peru
  • GSK Investigational Site
    Lima 27, Lima 27, Peru
  • GSK Investigational Site
    Cebu City, 6000, Philippines
  • GSK Investigational Site
    Davao City, 8000, Philippines
  • GSK Investigational Site
    Las Pinas, 1740, Philippines
  • GSK Investigational Site
    Manila, 1000, Philippines
  • GSK Investigational Site
    Quezon City, 1102, Philippines
  • GSK Investigational Site
    Sampaloc Manila, 1008, Philippines
  • GSK Investigational Site
    Konskie, 26-200, Poland
  • GSK Investigational Site
    Ponce, 00716, Puerto Rico
  • GSK Investigational Site
    San Juan, 00936-5067, Puerto Rico
  • GSK Investigational Site
    Bucharest, 020125, Romania
  • GSK Investigational Site
    Bucuresti, 020475, Romania
  • GSK Investigational Site
    Bucuresti, 021392, Romania
  • GSK Investigational Site
    Cluj Napoca, 400006, Romania
  • GSK Investigational Site
    Moscow, 115522, Russian Federation
  • GSK Investigational Site
    Saint Petersburg, 194291, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 190068, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 191015, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150003, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150023, Russian Federation
  • GSK Investigational Site
    Piestany, 921 12, Slovakia
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Stockholm, SE-171 76, Sweden
  • GSK Investigational Site
    Dalin Township, Chiayi County, 662, Taiwan
  • GSK Investigational Site
    Gueishan Township,Taoyuan County, 333, Taiwan

Showing the first 100 of 110 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, Wilson B, Molta C, Roth D, Gordon D. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016 Jun;25(7):699-709. doi: 10.1177/0961203315625119. Epub 2016 Mar 1. PubMed 26936891 ↗
  • van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Rheumatology (Oxford). 2020 Feb 1;59(2):281-291. doi: 10.1093/rheumatology/kez279. PubMed 31302695 ↗
  • Urowitz MB, Ohsfeldt RL, Wielage RC, Dever JJ, Zakerifar M, Asukai Y, Ramachandran S, Joshi AV. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study. Lupus Sci Med. 2020 Oct;7(1):e000412. doi: 10.1136/lupus-2020-000412. PubMed 33051264 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2008 to primary completion in Dec 2016, 102 months.

Results were first posted in Jan 2018, 1 year 1 month after primary completion.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 102 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2008
First posted
Jul 10, 2008
StartActual
May 30, 2008
Primary completionActual
Dec 9, 2016
CompletionActual
Dec 9, 2016
Results first posted
Jan 16, 2018
Last update
Dec 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00712933
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 10, 2008
Start date
May 30, 2008
Primary completion
Dec 9, 2016
Completion
Dec 9, 2016
Results posted
Jan 16, 2018
Last update
Dec 5, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion